Shares of French biotechnology company Abivax jumped 36% in Tuesday trading after the firm released new clinical trial data supporting its lead drug candidate, obefazimod.
The experimental treatment targets ulcerative colitis, a chronic inflammatory bowel disease, with the latest results confirming both safety and effectiveness profiles that have been critical to the company's development roadmap.
The move extends a rally that saw shares climb 31% earlier in the session, reflecting sustained buying interest as details of the trial outcomes emerged.
The market reaction underscores the high stakes attached to obefazimod, which remains Abivax's most advanced asset.
Investors are rewarding the de-risking of the clinical program, as positive data in this therapeutic area can significantly alter the valuation trajectory for mid-cap biotechs.
The move extends a rally that saw shares climb 31% earlier in the session, reflecting sustained buying interest as details of the trial outcomes emerged.
Abefazimod's progress is particularly notable given the competitive landscape in inflammatory bowel disease treatments.